GGrantIndex
← Leaderboards

John A Zaia

University Of Southern California

Google Scholar ↗PubMed ↗ORCID ↗
$8,207,353
Attributed
$8,207,353
Total exposure
18
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.9M · FY2005–17
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$20,388,550 · 20

By mechanism

P01$14,091,394 · 5
R01$3,248,740 · 2
M01$1,668,104 · 12
U01$1,380,312 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Gene Therapy”

Research focus

Gene TherapyClinical ResearchHematopoietic Stem CellsHuman Immunodeficiency Virus 1Aids TherapyHuman SubjectAidsHuman Therapy EvaluationRibozymesUnited States National Institutes Of HealthClinical TrialsHematopoietic Tissue TransplantationGrantFundingTransplantationCytomegalovirusCellsGenetic TransductionVirusSafetyRetroviridaeGene ExpressionNonhodgkin'S LymphomaComputer Retrieval Of Information On Scientific Projects Database

Grant awards (53)

Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient$312,304
U01 · FY2017 · CA · contact PI
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient$106,075
U01 · FY2016 · CA · contact PI
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient$496,292
U01 · FY2015 · CA · contact PI
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient$465,641
U01 · FY2014 · CA · contact PI
Evaluating New Targets of CMV Cellular Immunity$369,551
R01 · FY2013 · CA · contact PI
Evaluating New Targets of CMV Cellular Immunity$393,139
R01 · FY2012 · CA · contact PI
Evaluating New Targets of CMV Cellular Immunity$393,139
R01 · FY2011 · CA · contact PI
Evaluating New Targets of CMV Cellular Immunity$405,299
R01 · FY2010 · CA · contact PI
GENERAL CLINICAL RESEARCH CENTER$1
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: A PHASE I DOSE ESCALATION STUDY OF PEPTIDE VACCINES WITH ACTIVIT$435,965
M01 · FY2009 · RR · contact PI
LONG TERM FOLLOW-UP OF RECIPIENTS OF GENE TRANSFER$4,637
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE I DOSE ESCALATION STUDY OF PEPTIDE VACCINES WITH ACTIVIT$383,353
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE M$52,878
M01 · FY2008 · RR · contact PI
LONG TERM FOLLOW-UP OF RECIPIENTS OF GENE TRANSFER$4,806
M01 · FY2008 · RR · contact PI
LENTIVIRUS-BASED IMMUNOTHERAPY FOR AIDS$1,781,843
P01 · FY2007 · AI · contact PI
A Phase I Study of Lentivirus Safety During T-Cell Immunotherapy$418,285
P01 · FY2007 · AI · contact PI
Evaluation New Targets of CMV Cellular Immunity$407,717
R01 · FY2007 · AI · contact PI
CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT$107,572
M01 · FY2007 · RR · contact PI
LONG TERM FOLLOW-UP OF RECIPIENTS OF GENE TRANSFER$2,907
M01 · FY2007 · RR · contact PI
LENTIVIRUS-BASED IMMUNOTHERAPY FOR AIDS$1,777,502
P01 · FY2006 · AI · contact PI
A Phase I Study of Lentivirus Safety During T-Cell Immu$428,913
P01 · FY2006 · AI · contact PI
Evaluation New Targets of CMV Cellular Immunity$419,895
R01 · FY2006 · AI · contact PI
CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT$172,014
M01 · FY2006 · RR · contact PI
LENTIVIRUS-BASED IMMUNOTHERAPY FOR AIDS$75,000
P01 · FY2006 · AI · contact PI
LONG TERM FOLLOW-UP OF RECIPIENTS OF GENE TRANSFER$4,354
M01 · FY2006 · RR · contact PI
LENTIVIRUS-BASED IMMUNOTHERAPY FOR AIDS$1,759,151
P01 · FY2005 · AI
Evaluation New Targets of CMV Cellular Immunity$430,000
R01 · FY2005 · AI
A Phase I Study of Lentivirus Safety During T-Cell Immu$412,957
P01 · FY2005 · AI
CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT$161,762
M01 · FY2005 · RR
LONG TERM FOLLOW-UP OF RECIPIENTS OF GENE TRANSFER$2,067
M01 · FY2005 · RR
LENTIVIRUS-BASED IMMUNOTHERAPY FOR AIDS$1,755,949
P01 · FY2004 · AI
Evaluation New Targets of CMV Cellular Immunity$430,000
R01 · FY2004 · AI
A Phase I Study of Lentivirus Safety During T-Cell Immu$412,205
P01 · FY2004 · AI
CMV-Specific Cellular Immunity in Recipients of BMT$133,774
M01 · FY2004 · RR
Long Term Follow-up of Recipients of Gene Transfer$10,697
M01 · FY2004 · RR
ANTI-HIV RNA TRANSDUCTION INTO BLOOD STEM CELLS IN AIDS$1,754,493
P01 · FY2002 · AI
IMPROVED RETROVIRAL GENE THERAPY IN AIDS LYMPHOMA$0
P01 · FY2002 · CA
CLINICAL TRIALS CENTER$0
P01 · FY2002 · AI
TRANSDUCTION OF HIV POSITIVE CD34+ PERIPHERAL BLOOD PROGENITOR CELLS$0
M01 · FY2002 · RR
ANTI-HIV RNA TRANSDUCTION INTO BLOOD STEM CELLS IN AIDS$1,459,491
P01 · FY2001 · AI
TRANSDUCTION OF ANTI-HIV RNA INTO BLOOD STEM CELLS IN A*$317,960
P01 · FY2001 · AI
TRANSDUCTION OF HIV POSITIVE CD34+ PERIPHERAL BLOOD PROGENITOR CELLS$155,764
M01 · FY2001 · RR
ANTI-HIV RNA TRANSDUCTION INTO BLOOD STEM CELLS IN AIDS$75,000
P01 · FY2001 · AI
CLINICAL TRIALS CENTER$0
P01 · FY2001 · AI
CLINICAL TRIALS CENTER$0
P01 · FY2001 · AI
CLINICAL TRIALS CENTER$0
P01 · FY2001 · AI
IMPROVED RETROVIRAL GENE THERAPY IN AIDS LYMPHOMA$0
P01 · FY2001 · CA
TRANSDUCTION OF HIV POSITIVE CD34+ PERIPHERAL BLOOD PROGENITOR CELLS$0
M01 · FY2001 · RR
ANTI-HIV RNA TRANSDUCTION INTO BLOOD STEM CELLS IN AIDS$1,424,808
P01 · FY2000 · AI
CLINICAL TRIALS CENTER$237,837
P01 · FY2000 · AI
TRANSDUCTION OF HIV POSITIVE CD34+ PERIPHERAL BLOOD PROGENITOR CELLS$35,553
M01 · FY2000 · RR
IMPROVED RETROVIRAL GENE THERAPY IN AIDS LYMPHOMA$0
P01 · FY2000 · CA
TRANSDUCTION OF HIV POSITIVE CD34+ PERIPHERAL BLOOD PROGENITOR CELLS$0
M01 · FY2000 · RR